Imogen Mansfield
Cantor Fitzgerald & Co., Research Division
Good morning, everyone. I am Imogen Mansfield. I’m a Biotech Analyst at Cantor, and I am delighted to be joined today by 2 legends, the CEO of Eikon, Roger Perlmutter; and Dr. Tim Yap, who is a legendary clinical trialist and physician at MD Anderson. So welcome.
Thank you for joining to discuss PARP1 with us. We will be going through PARP1 biology, discussing the unmet needs left by the first generation of PARP inhibitors and then going through Eikon’s programs and spending some time at the end talking about Werner helicase.
So to kick us off, Dr. Yap, would you like to tell us a little bit about your background and the trials that you’re involved with for the PARP1 field and I guess, synthetic lethality more broadly. And just to confirm, we’ve just discussed this top line, but Dr. Yap is involved in several programs with Eikon and will not be sharing any nonpublic information today.
Timothy Yap
Thanks so much, Imogen. Good morning, everyone, and really thank Imogen for the kind invitation. Great honor to be here with Roger. And my name is Tim Yap. I’m at MD Anderson. I’ve been here for 10 years. Before that, I was at the Institute of Cancer Research and the Royal Marsden Hospital for about 12 years, where I’ve had a big interest in synthetic lethality, being involved with the development of many first-generation PARP inhibitors and then, of course, now the new generation PARP1 selective agents and also many other DDR agents. And also, I guess, Werner helicase that we’ll be covering